IceCure Medical Ltd. Ordinary Shares
ICCMIceCure Medical Ltd. is a medical technology company specializing in cryoablation solutions for minimally invasive treatment of tumors. Founded in Israel, the company develops and commercializes advanced cryoablation systems designed to precisely destroy cancerous tissues, primarily in breast, kidney, liver, and lung cancers. IceCure's innovative devices leverage liquid nitrogen and other cryogenic techniques to provide outpatient treatment options with reduced recovery times.
Company News
IceCure Medical Ltd. (NASDAQ: ICCM) announced a $5.5 million private placement of 1.83 million ordinary shares and warrants priced at $3.00 per share, representing a premium to the previous closing price. The offering is expected to close on June 18, 2026, with proceeds intended for working capital and general corporate purposes. The company also...
IceCure Medical reported a 70% increase in its U.S. active commercial install base for ProSenseĀ® breast cancer cryoablation systems following FDA marketing authorization in October 2025. The growth is driven by FDA clearance, clinical guideline support from the American Society of Breast Surgeons, increased physician demand demonstrated at major...
IceCure Medical announced positive clinical data for its ProSenseĀ® cryoablation system at ECIO 2026, showing 89.4% recurrence-free rate for kidney tumors ā¤3 cm and 100% excellent cosmetic outcomes in breast cancer patients. The company also reported 92.9% fibroadenoma volume reduction at 12 months. A dedicated breast cryoablation course was he...
IceCure Medical Ltd. (NASDAQ: ICCM) has been granted an additional 180-day compliance period until November 9, 2026 to regain compliance with Nasdaq's minimum $1.00 bid price requirement. The company failed to meet the requirement during the first 180-day period ending May 11, 2026, and may implement a reverse share split to cure the deficiency.
IceCure Medical reported Q1 2026 results with global revenue growth of 26% to $911,000 and North America sales up 84%. Following FDA clearance for breast cancer treatment, active U.S. customer accounts increased 46% to 19 accounts. The company is expanding its U.S. sales footprint to eight regions and expects its ChoICE post-marketing study to ac...
